TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05239026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional treadmill walking
Description: Participants will walking on a treadmill for 6 5-minute Blocks. Participants will walk at self-selected cadence during Blocks 1-3. Speed will progressively increase during Blocks 4-6.
Study: NCT06059547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for Visugromab (CTL-002)
Study: NCT04736576

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable device
Description: As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable device
Description: As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
Study: NCT05584839

Intervention type: OTHER
Intervention: Statistically Analysis
Description: The study was planned as a quantitative research. Socio-demographic information form, anthropometric measurements of hand grip strength, palm length, hand width length, wrist circumference length, Visual Analog Scale scale, EMG findings will be evaluated by hand dynamometer.
Study: NCT05997316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Participants will work with a psychologist towards achieving a 16 hour fasting period, 2-3 days per week. The intervention will last 12 weeks, with different intervention materials gradually introduced over the course of the 12 weeks.
Study: NCT06597006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg, inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg to ≥16 kg, or inclisiran sodium 100 mg s.c. for participants with body weight \<16 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Study: NCT06662435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GYNCOG
Description: Participants in the GYNCOG arm will be asked to participate in a home-based cognitive training program utilizing BrainHQ. Participants will be instructed to use the Brain HQ app for approximately 2.5 hours per week. Patients will be provided with a calendar to help keep track of daily BrainHQ use, including the number of exercises completed and the amount of time spent on the app per day.~Patients will be asked to undergo the exercises that target the speed and accuracy of information processing. Examples of the exercises include:~Double Decision: This exercise tests your ability to quickly identify and choose between two options.~Eye for Detail: It challenges participants to spot small differences between two similar images.~Participants will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week (i.e., 2.5 hours per week) for 10 weeks, for a total of approximately 25 hours.
Study: NCT05598619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Colon delivered vitamin C (ascorbic acid) for 12 weeks
Study: NCT06498856

Intervention type: OTHER
Intervention: Isotonic saline infusion
Description: Volume expansion with one liter of isotonic saline intravenously over two hours.
Study: NCT06511635

Intervention type: OTHER
Intervention: Qualitative interview
Description: Interview between participant and a researcher, in order to identity the determinants of participation in a clinical trial among participants in the CMVictory vaccine trial.

Intervention type: OTHER
Intervention: Quantitative questionnaire
Description: Anonymous online survey using a 3-part questionnaire, studying knowledge of clinical research and the determinants of participation in a preventive vaccine study in a population of young women (aged 18-40).
Study: NCT06034106

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pomegranate (Punica granatum) peel compress
Description: Pomegranate (Punica granatum) peel compress was applied 3 days a week for 3 weeks by turning the powder into porridge check.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pomegranate (Punica granatum) peel compress
Description: Pomegranate (Punica granatum) peel compress was applied 3 days a week for 3 weeks by turning the powder into porridge check.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hot compress
Description: Hot compress was applied 3 days a week for 3 weeks.
Study: NCT05738733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MsChief Classic Natural Lubricant
Description: Apply the desire amount of lubricant on the body to make it more sensitive.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MsChief Ylang Ylang Natural Lubricant
Description: Apply the desire amount of lubricant on the body to make it more sensitive.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MsChief Vanilla & Citrus Natural Lubricant
Description: Apply the desire amount of lubricant on the body to make it more sensitive.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MsChief Tea & Peach Natural Lubricant
Description: Apply the desire amount of lubricant on the body to make it more sensitive.
Study: NCT05395260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL-101
Description: FL-101 200mg IV
Study: NCT06323837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of mirtazapine (MZP) to increase methamphetamine (MA) abstinence among treatment-seeking medication for opioid use disorder (MOUD) adults.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match.
Study: NCT06516068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1893
Description: HRS-1893
Study: NCT05410249

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum IL10 By ELISA
Description: measurement Of IL10 by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum IL10 By ELISA
Description: measurement Of IL10 by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: SNP -3279 A/C of FOXP3
Description: Genotyping of -6054 del/ATT will be performed using the real-time polymerase chain reaction.

Intervention type: DIAGNOSTIC_TEST
Intervention: SNP -3279 A/C of FOXP3
Description: Genotyping of -6054 del/ATT will be performed using the real-time polymerase chain reaction.

Intervention type: DIAGNOSTIC_TEST
Intervention: SNP-924 A/G Of FOXP3
Description: Genotyping of -924 A/G polymorphisms was performed using the real-time polymerase chain reaction.

Intervention type: DIAGNOSTIC_TEST
Intervention: SNP-924 A/G Of FOXP3
Description: Genotyping of -924 A/G polymorphisms was performed using the real-time polymerase chain reaction.
Study: NCT04992078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVIO/CORI Surgical System
Description: Unicompartmental knee replacement with robotic assistance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-robotic conventional instrumentation
Description: Unicompartmental knee replacement with non-robotic conventional instrumentation
Study: NCT05598619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Colon delivered vitamin C (ascorbic acid) for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Colon delivered placebo once a day for 12 weeks
Study: NCT05813730

Intervention type: OTHER
Group type: OTHER
Intervention: urinary creatinine excretion measurement
Description: Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.
Study: NCT05771077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly(Amidoamine) dendrimer
Description: to evaluate the Remineralizing effect of Poly Amido Amine Dendrimer, Nanohydroxy apatite \& Their Combination on demineralized enamel \& Their Clinical Efficacy on White Spot lesion
Study: NCT04704310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing exercise training for adults with COPD: The roles of peers and functional tasks
Description: A proof-of-concept online 8-week exercise training program for adults with COPD that incorporates both a peer mentorship and a functional tasks component.
Study: NCT05611983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensory relearning
Description: feasibility of early sensory relearning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensory relearning
Description: feasibility of early sensory relearning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensory relearning
Description: feasibility of early sensory relearning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensory relearning
Description: feasibility of early sensory relearning
Study: NCT05359263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: The intervention arm consists of dapagliflozin 10 mg orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The comparator arm consists of placebo orally once daily
Study: NCT04700241

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate
Description: Acute intervention (5.5 hours)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute intervention (5.5 hours)
Study: NCT06663995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study Group
Description: It will include 16 patients with periodontitis stage II, grade B, at least 2 sites with pocket PD = 4-5 mm and CAL = 3-4 mm each will receive non-surgical periodontal therapy followed by application of propolis gel.~After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo) group
Description: After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).
Study: NCT06664281

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SIT
Description: sprint interval training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SIT combined RIPC
Description: sprint interval training combined with remote ischemic preconditioning
Study: NCT06663059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle
Description: Each treatment cycle is 3 weeks long (Q3W), with a total of 2 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle
Description: Each treatment cycle is 3 weeks long (Q3W), with a total of 4 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion.
Study: NCT06663891

Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI with EEG per MRI
Description: 2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent.~Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,

Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI with EEG per MRI
Description: 2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent.~Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,
Study: NCT06661109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention (Kinesio Taping) group
Description: No randomized study was found investigating the effect of kinesio taping on comfort levels in women having a cesarean delivery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention (Kinesio Taping) group
Description: No randomized study was found investigating the effect of kinesio taping on comfort levels in women having a cesarean delivery.
Study: NCT06663878

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MWAV201
Description: Nonreplicating, recombinant gene transfer vector
Study: NCT06663683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip thrust
Description: The subjects in Hip Thrust (HT) group will be instructed to perform low-load gluteus activation exercises, which included single-leg bridges, clamshells and quadruped hip extensions. One set of ten repetitions or steps will perform for each exercise. In this training program three stages which focused on enhancing hypertrophy and strength of the hip extensors in sequence. During the training period, the subjects will be instructed to maintain their usual daily activities and diet. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between the sessions. Hip thrust training 3 sets with 10 repetitions in each set and 2 minutes rest between each set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back squat
Description: In Back Squat (BS) resistance training the subjects starts with the standing position with the feet flat on the floor, the knees and hips in a neutral, extended anatomical position, and the spine in an upright position with preservation of its natural curves. The squat movement will begin with the descent phase as the hips, knee and ankles flex. A common instruction will be given to the subjects to descend until the top of the thigh is at least parallel with ground and the hip joint is at least level with or slightly below the knee joint. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between sessions. Back squat training 3 sets with 10 repetitions in each set \& 2 minutes rest between each set.
Study: NCT05840965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot muscle strengthening
Description: A specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The exercises are: short foot exercise, toe spread out, first toe extension, second to fifth toe extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foot orthotics
Description: Custom-made foot orthotics
Study: NCT05513638

Intervention type: DIAGNOSTIC_TEST
Intervention: the clinical use of artificial intelligence in the diagnosis of prostate cancer
Description: Each study site will enroll consecutive eligible patients and randomize them to either (a) a group with human-based interpretation or (b) a group with human-artificial intelligence interactive interpretation, both of which are utilized as standards of care.

Intervention type: DIAGNOSTIC_TEST
Intervention: the clinical use of artificial intelligence in the diagnosis of prostate cancer
Description: Each study site will enroll consecutive eligible patients and randomize them to either (a) a group with human-based interpretation or (b) a group with human-artificial intelligence interactive interpretation, both of which are utilized as standards of care.
Study: NCT06325995

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiation therapy
Description: 66-74 Gy in 33-37 daily fractions of 2 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Description: 57.5-65 Gy in 23-26 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
Study: NCT06063941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lugol's iodine solution
Description: 1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Lugol's iodine solution
Description: Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.
Study: NCT06103370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-educator-based network
Description: The intervention is a social network-based method of dispersing HIV knowledge, HIV self-testing (HIVST) kits, and naloxone in social networks of people who inject drugs (PWID). It targets index participants (peers) to receive training on HIVST, peer education, and linkage to syringe service programs (SSPs) for HIV services.
Study: NCT06192628

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parkinson's Exercise and Education Programme
Description: A 12 week programme of exercise and education~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist only)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parkinson's Exercise and Education Programme and Behavioural Change
Description: A 12-week programme of exercise, education and behavioural change techniques to support exercise adherence and exercise self-efficacy~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist and participant)~Additional techniques addressing behavioural regulation include firstly, an exercise diary completed independently at home, secondly, the rationale and the intended functional benefit and expectations of the exercise programme clearly explained, thirdly individual weekly conversations to reflect on progress, expectations, solutions to barriers, and goals. Finally, peer support is strongly encouraged through the in-class support, and a social media networking group.
Study: NCT05212259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen type II (40 mg/day)
Description: 4 capsules per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen type II (80mg/day)
Description: 4 capsules per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen type II (120 mg/day)
Description: 4 capsules per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
Description: 4 capsules per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules per day
Study: NCT06653686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with oral febuxostat.
Description: Extracorporeal high-frequency hyperthermia combined with oral febuxostat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: The control group subjects were administered oral febuxostat.
Study: NCT04641923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adhesion barrier
Description: Adhesion barrier application at the time of first surgery